Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-102 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | ABT-102 Tablets, 4 mg BID |
| 2 | ACTIVE_COMPARATOR | ABT-102 Tablets BID, escalating dose |
| 3 | ACTIVE_COMPARATOR | ABT-102 Tablets BID, escalating dose |
| 4 | PLACEBO_COMPARATOR | Placebo Tablets, BID |
| Name | Type | Description |
|---|---|---|
| ABT-102 | DRUG | BID tablets, 7 days of treatment |
| Placebo | DRUG | BID tablets, 7 days of treatment |
Inclusion Criteria: * Males and Females with a condition of general good health. * Must be willing to participate in all study-related procedures. Exclusion Criteria: * History of significant sensitivity to any drug. * Allergy to soy lecithin, soybeans, soybean oil, or other soybean derivatives. ...
ABT-102 is an investigational small molecule developed by Abbott Laboratories. It was studied in a Phase 1 clinical trial in healthy adult volunteers to evaluate its safety, tolerability, and pharmacokinetics. It is not an approved medicine and remains in clinical development.
ABT-102 targets TRPV1, the transient receptor potential vanilloid 1 receptor. It acts as a TRPV1 antagonist, meaning it is designed to block activity at this receptor. TRPV1 is a molecular target of interest in pain and sensory signaling research.
ABT-102 is developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. Abbott sponsored the Phase 1 study of ABT-102 conducted in the United States.
ABT-102 is in Phase 1 clinical development. Its single recorded trial, NCT00854659, was a Phase 1 study that has been completed. ABT-102 is investigational and has not been approved by the FDA for any indication.
ABT-102 was evaluated in one clinical trial, NCT00854659, titled A Safety, Tolerability and Pharmacokinetic Study of ABT-102 in Healthy Subjects. The Phase 1 trial enrolled 36 healthy volunteers in the United States, was randomized, double-blind, and placebo-controlled, and is now completed.